News und Analysen
Why Advanced Accelerator Application SA Stock Jumped Higher Today
Shares of Advanced Accelerator Application (NASDAQ: AAAP) are up 12% as of 11:23 a.m. EDT after Bloomberg reported that Novartis (NYSE: NVS) is considering acquiring the radiopharmaceutical....
Why Aurinia Pharmaceuticals Could Be a Gold Mine for Growth Investors
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) stock has already tripled this year, on renewed hopes of success for an experimental lupus treatment. Despite this year's big run-up, this....
Why Are Cancer Drugs So Expensive?
All drugs are costly to produce, but cancer drugs are notoriously expensive to push through to market, and every year, treatments get more and more expensive. In this clip from Industry Focus:....
How Much Does It Really Cost to Develop a Cancer Drug?
Cancer drugs can cost hundreds of thousands of dollars and increasing complexity suggests that prices for these drugs are going higher. For instance, Novartis (NYSE: NVS) won approval for a new....
Here's Why Glaukos Corp. Stock Is Stumbling Today
Shares of Glaukos Corp. (NYSE: GKOS), a medical device manufacturer with an eye on glaucoma, are slipping today. Just ahead of the company's investors day meeting, management made some adjustments....
Are You Buying Gilead Sciences, Inc. for the Wrong Reason?
Gilead Sciences (NASDAQ: GILD) is up about 12% over the last week or so since Novartis (NYSE: NVS) got its chimeric antigen receptor T-cell (CAR-T) therapy Kymriah approved by the FDA.That's just....
Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better
Investors have been wondering for a few years now when Gilead Sciences (NASDAQ: GILD) would spend some of its massive cash hoard and acquire a new company, and this week, Gilead put those wonders....
3 Reasons Gilead Sciences Jumped to Buy Kite Pharma
Gilead Sciences Inc. (NASDAQ: GILD) might be the most disciplined capital allocator in biotech. For years, its management has resisted calls from the peanut gallery to make a big acquisition,....
Novartis $475,000 Price Tag Sets the Stage for a Price War With Gilead Sciences
On Monday, Gilead Sciences' (NASDAQ: GILD) wowed investors with an $11.9 billion deal to buy clinical-stage CAR-T drugmaker Kite Pharma (NASDAQ: KITE), and on Wednesday, the FDA approved Novartis'....
Why Analog Devices, Gilead Sciences, and Universal Display Jumped Today
The major benchmarks posted gains on Wednesday, as geopolitical fears and hurricane concerns gave way to positive economic news. A report released by the U.S. Department of Commerce showed that....
Can Gilead Sciences Squeeze $12 Billion From Kite Pharma?
Gilead Sciences, Inc. (NASDAQ: GILD) just took a bold leap into the unknown with an agreement to acquire Kite Pharma Inc. (NASDAQ: KITE) for $180 per share or about $11.9 billion. Gilead's last....
3 Reasons to Applaud Gilead Sciences' Acquisition of Kite Pharma
Finally.Gilead Sciences (NASDAQ: GILD) announced on Monday that it was acquiring Kite Pharma (NASDAQ: KITE) for $11.9 billion. Investors had long waited for the big biotech to make a deal. One....
3 Stocks to Buy With Dividends Yielding More Than 3%
Dividend stocks offer both income and long-term growth prospects. Smart dividend investors focus on the stocks that have the best chances of giving them both, maximizing their returns. Among
3 Key Things Every CAR-T Investor Should Watch
A long-awaited breakthrough in cancer treatment, chimeric antigen receptor T-cell (CAR-T) therapy, could finally hit the market later this year.First-to-market advantage will likely to go Novartis
Is It Too Late to Get In on This Millionaire-Maker Stock?
Corcept Therapeutics (NASDAQ: CORT) is one hot biotech stock no matter how you look at it. Shares have nearly quintupled in value in just three years. So far in 2017, Corcept stock is up around 70%.
Why You're Smart to Buy Vertex Pharmaceuticals Stock
You might look at Vertex Pharmaceuticals (NASDAQ: VRTX) stock and shake your head at its valuation. After soaring more than 70% so far in 2017, shares of the biotech now trade at a whopping 180 times
Is Juno Therapeutics Stock Still a Strong Buy?
Shares of the clinical-stage biotech Juno Therapeutics (NASDAQ: JUNO) rose by a healthy 22% last month, according to S&P Global Market Intelligence. The drugmaker's shares seemed to get a lift from
Biotech-Branche: Steuerreform kann die nächste Übernahmewelle auslösen!
Liebe Leser,
Donald Trump hat im Wahlkampf angekündigt, dass er mit einer Steuerreform dafür sorgen wird, dass die US-Unternehmen das aus steuerlichen Gründen im Ausland „geparkte“ Geld zurück....
Zukunft und Status der Biotech-Branche
Liebe Leser,
die Aktien aus den Gesundheitsbranchen Pharma und Biotech gehörten im US-Wahlkampf 2015/2016 zu den größten Verlierern.
Besonders die demokratischen Kandidaten Hillary Clinton und....
Novartis: Warum ist der Umsatz gefallen?
Lieber Leser,
Novartis hat am 25. April die Ergebnisse für das erste Quartal veröffentlicht. Die Umsätze sind gegenüber dem ersten Quartal 2016 gestiegen, gegenüber dem Vorquartal jedoch gefallen.....
BB Biotech: Quartalsergebnis erfreulich, Aktie schwach!
Liebe Leser,
letzte Woche überschlugen sich die Nachrichten bei BB Biotech. Die wichtigsten Nachrichten, die letzte Woche das Unternehmen und dessen Kurse bewegt haben waren folgende:
Gute....
BB Biotech: Kommt der nächste Anstieg zum Jahreshoch? Trading-Chance!
Der Kursanstieg nach den guten Zahlen am 21. April ist schnell wieder verpufft, aber die Unterstützung bei 51,05 Euro konnte dem Druck widerstehen und der Kurs drehte bei 51,16 Euro wieder nach....
BB Biotech: Die Zahlen des 1. Quartals
Liebe Leser,
für die ersten drei Monate des laufenden Jahres verzeichnete BB Biotech eine Gesamtrendite von 7.7% in CHF und 7.1% in Euro. Das Portfolio schloss das Quartal mit einer positiven....
BB Biotech: Starke Quartalszahlen
Liebe Leser,
das Warten hat ein Ende: Der deutsche Aktien-Leitindex DAX hat heute ein neues Allzeithoch erreicht und notiert zum ersten Mal seit dem Index-Start 1988 über der Marke von 12.400....
BB Biotech: Quartalsergebnis erfreulich, Aktie schwach!
Lieber Leser,
BB Biotech vermeldete nun ein „erfreuliches Quartalsergebnis“, wie es heißt. Dabei ist der Reingewinn in Franken bemessen auf 375 Millionen gestiegen. Im Vorjahr gab es im selben....